Tag: Saluda Medical
Saluda announces plans to present new EVOKE study data at NANS...
Saluda Medical has announced that its data will be presented at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas,...
Saluda receives US FDA approval for MRI labelling of Evoke spinal...
Saluda Medical has announced that the US Food and Drug Administration (FDA) has approved magnetic resonance imaging (MRI) conditional labelling for its Evoke system,...
Health economic data show cost-dominance of Saluda’s EVOKE system over open-loop...
Saluda Medical has announced the publication of new health economic data in the Clinical Journal of Pain that provides “the strongest ever economic case” for the...
Saluda Medical announces presentation of 36-month EVOKE trial data at NANS...
Saluda Medical has announced that late-breaking data from the "landmark" EVOKE clinical trial was presented at the recent North American Neuromodulation Society (NANS) annual...
Saluda Medical initiates US commercialisation of the Evoke spinal cord stimulation...
Saluda Medical has announced plans for a limited commercial release of its Evoke spinal cord stimulation (SCS) system in the USA, with a full commercial...
Saluda Medical presents data on 24-month holistic response to spinal cord...
Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...
Saluda Medical raises US$125m to boost Evoke spinal cord stimulation offering
Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...
Saluda Medical receives FDA approval for the Evoke spinal cord stimulation...
Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...